During the last session, Syros Pharmaceuticals Inc (NASDAQ:SYRS)’s traded shares were 2.02 million, with the beta value of the company hitting 1.29. The 52-week high for the SYRS share is $8.17, that puts it down -3304.17 from that peak though still a striking 25.0% gain since the share price plummeted to a 52-week low of $0.18. The company’s market capitalization is $6.33M, and the average intraday trading volume over the past 10 days was 2.35 million shares, and the average trade volume was 8.28 million shares over the past three months.
Syros Pharmaceuticals Inc (SYRS) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 2.50. SYRS has a Sell rating from 0 analyst(s) out of 7 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 7 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.71.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Syros Pharmaceuticals Inc (NASDAQ:SYRS) trade information
Syros Pharmaceuticals Inc (SYRS) registered a -3.72% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -3.72% in intraday trading to $0.24, hitting a weekly high. The stock’s 5-day price performance is -0.25%, and it has moved by -91.36% in 30 days. Based on these gigs, the overall price performance for the year is -95.20%. The short interest in Syros Pharmaceuticals Inc (NASDAQ:SYRS) is 2.23 million shares and it means that shorts have 0.1 day(s) to cover.
The consensus price target of analysts on Wall Street is $10, which implies an increase of 97.6% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $5 and $15 respectively. As a result, SYRS is trading at a discount of -6150.0% off the target high and -1983.33% off the low.
Syros Pharmaceuticals Inc (SYRS) estimates and forecasts
Statistics show that Syros Pharmaceuticals Inc has outperformed its competitors in share price, compared to the industry in which it operates. Syros Pharmaceuticals Inc (SYRS) shares have gone down -95.93% during the last six months, with a year-to-date growth rate more than the industry average at 65.53% against 17.10. In the rating firms’ projections, revenue will decrease -95.47% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 450k as predicted by 4 analyst(s).
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 21.16%. While earnings are projected to return 73.32% in 2024.
SYRS Dividends
Syros Pharmaceuticals Inc is due to release its next quarterly earnings in January. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Syros Pharmaceuticals Inc (NASDAQ:SYRS)’s Major holders
Syros Pharmaceuticals Inc insiders own 0.74% of total outstanding shares while institutional holders control 75.59%, with the float percentage being 76.15%.
